Loading...
01/11 16:21
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals: strong revenue growth and improved gross margins are offset by challenges in Medicare Advantage authorizations and increased operating expenses. Positive factors like international growth and advertising efficiency are countered by uncertainties in pipeline conversion and lack of shareholder return plans. Management's vague responses in the Q&A add to the uncertainty. Despite strong guidance, the absence of a shareholder return plan and ongoing operational challenges suggest a neutral stock price movement in the short term.
Revenue $9,800,000, up 162% year-over-year, driven by higher number of revenue units and higher average selling price (ASP).
Revenue Units Delivered 182 units, up 100% year-over-year, reflecting higher velocity of revenues, particularly from Medicare Part B patients.
Average Selling Price (ASP) Approximately $54,000, up 31% year-over-year, due to the inclusion of Medicare fees.
Medicare Part B Revenue Contribution 60% of total revenue, up from 57% in the previous quarter, indicating success in educating this patient population.
Medicare Advantage Revenue Contribution 17% of total revenue, up 18% year-over-year, but growth lagging due to high denial rates.
International Revenue $1,300,000, representing 13% of quarterly revenue, up 42% year-over-year, primarily from Germany.
Patient Pipeline 1,482 patients, up 33% year-over-year, with 700 new patients added in Q1, despite lower than planned due to lead generation issues.
Cost per Pipeline Add $2,300, up 31% year-over-year, reflecting higher advertising spend and lead generation challenges.
Backlog 249 patients, down 9% year-over-year, due to fewer pre-authorizations from Medicare Advantage plans.
Gross Margin 67.2%, up from 61.2% year-over-year, driven by higher ASP and fixed cost absorption.
Operating Expenses $10,100,000, up 64% year-over-year, driven by higher headcount, advertising spend, and R&D expenses.
Operating Loss $3,500,000, down 9% year-over-year from $3,900,000.
Net Loss $3,500,000 or $0.08 per share, compared to a net loss of $3,800,000 or $0.10 per share in the prior year.
Cash and Cash Equivalents $21,500,000 as of 03/31/2025, sufficient to fund operations for at least the next twelve months.
Cash Used for Operations $2,700,000 in Q1, consistent with plans to ramp hiring and marketing spend.
Product Upgrades: Introduced two product upgrades: the Mark II clinical unit and the MyoPro 2X, aimed at improving patient outcomes and expanding distribution channels.
New Device Launch: Launched the MyoPro 2X, an upgraded version of the MyoPro 2+, designed to enhance independent device use and support daily functional tasks.
Market Expansion: Expanded presence in the orthotics and prosthetics (O and P) channel, training over 300 clinicians to assess patients and build MyoPro pipelines.
International Revenue Growth: International business, primarily in Germany, generated over $1,300,000 in revenue, reflecting a 42% year-over-year increase.
Insurance Contracts: Executed contracts covering 25,000,000 lives, including new state Blue Cross Blue Shield plans, to improve patient access.
Manufacturing Capacity: Moved to a new facility in Burlington, Massachusetts, increasing manufacturing capacity to 120 units per month.
Advertising Efficiency: Adjusted advertising strategy in response to Meta's algorithm changes, resulting in a record number of leads in April.
Strategic Focus: Continued focus on product development and marketing to enhance lead generation and patient engagement.
Operational Adjustments: Successfully adapted operations to external challenges, including changes in advertising policies and reimbursement environments.
Advertising Efficiency: Changes in Meta's advertising policies impacted lead generation efforts, resulting in higher costs per pipeline initially. Adjustments were made to improve efficiency, leading to a record number of leads in April.
Authorization Challenges: Medicare Advantage and certain commercial insurance plans continue to deny or delay authorizations for a large percentage of physician orders for MyoPro, affecting revenue and backlog.
Pipeline Conversion Rate: The percentage of pipeline that was authorized in Q1 was lower than typical, attributed to fewer pre-authorizations from Medicare Advantage plans and a backlog of pipeline adds.
Regulatory Environment: The company is facing challenges with high denial rates from insurance companies, particularly Medicare Advantage, which is affecting patient access to MyoPro.
Supply Chain and Operational Capacity: The company is expanding its manufacturing capacity and training more clinicians, but operational challenges remain due to the complexity of the reimbursement process.
Economic Factors: The overall healthcare environment is experiencing pressures, including changes in insurance policies and reimbursement rates, which could impact future revenue growth.
Product Development: Introduced two product upgrades: Mark II clinical unit and MyoPro 2X, aimed at improving independent device use.
Market Expansion: Expanded R&D capabilities and O and P distribution channel to build patient pipelines.
Training Initiatives: Conducted training for over 300 CPOs to assess patients and build MyoPro pipelines.
Insurance Contracts: Executed contracts covering 25 million lives, including new state Blue Cross Blue Shield plans.
International Growth: International business, primarily in Germany, generated over $1.3 million in revenue.
Q2 Revenue Guidance: Expect revenue between $9 million and $9.5 million, up 20% to 26% year over year.
2025 Revenue Guidance: Continue to expect 2025 revenue in the range of $50 million to $53 million, representing growth of 54% to 66% over 2024.
Cash Flow Outlook: Expect negative cash flows through Q3 2025, with a return to positive cash flow by Q4 2025.
Gross Margin Expectations: Expect gross margins to approach 70% in the second half of the year.
Shareholder Return Plan: Myomo has not announced any share buyback or dividend program during this earnings call. The focus remains on growth and operational investments.
The earnings call reveals several concerning factors: declining gross margins, increased operating expenses, and widening losses. While there are strategic plans for revenue growth and cost management, the lack of clear guidance on returning to positive adjusted EBITDA and the impact of debt raise concerns. The Q&A session highlights uncertainties, particularly in the international market and the China partnership. These negatives outweigh the positives, leading to a negative sentiment prediction for the stock price over the next two weeks.
The earnings call presents a mixed picture. While there is positive guidance with expected revenue growth and international expansion, challenges such as flat Q3 guidance, increased material costs, and declining authorization rates temper optimism. The Q&A session highlights management's efforts to address advertising and reimbursement issues, but uncertainties remain. The lack of clear guidance on pipeline adds and workforce impacts further adds to the neutral sentiment. Given the absence of market cap data, the overall reaction is likely neutral, with no strong catalysts for significant stock movement in either direction.
The earnings call presents mixed signals: strong revenue growth and improved gross margins are offset by challenges in Medicare Advantage authorizations and increased operating expenses. Positive factors like international growth and advertising efficiency are countered by uncertainties in pipeline conversion and lack of shareholder return plans. Management's vague responses in the Q&A add to the uncertainty. Despite strong guidance, the absence of a shareholder return plan and ongoing operational challenges suggest a neutral stock price movement in the short term.
The earnings call shows strong financial performance with a 162% revenue increase and improved gross margins. Despite higher expenses, the company achieved operating cash flow breakeven and provided optimistic guidance for 2025. The Q&A section highlights effective advertising adjustments and sustainable improvements. Although there are concerns about pipeline authorization rates and some unclear management responses, the overall sentiment remains positive, especially with the expansion into international markets and a significant increase in Medicare revenue contribution.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
